Validating the 2023 FIGO staging system: A nomogram for endometrioid endometrial cancer and adenocarcinoma
Cancer Medicine · 2024
DOI: 10.1002/cam4.7216 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yifan Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Nomograms, Endometrial Neoplasms, Neoplasm Staging, SEER Program. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anhui Provincial Department of Science and Technology.
Abstract (Originalsprache)
Background
To find the factors impacting overall survival (OS) prognosis in patients with endometrioid endometrial carcinoma (EEC) and adenocarcinoma and to establish a nomogram model to validate the 2023 International Federation of Obstetrics and Gynecology (FIGO) staging system for endometrial cancer.
Methods
Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) training cohort. An independent validation cohort was obtained from the First Affiliated Hospital of Anhui Medical University between 2008 and 2023. Cox regression analysis identified independent prognostic factors for OS in EEC and adenocarcinoma patients. A nomogram predicting OS was developed and validated utilizing the C‐index, calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA). The relationship between the tumor grade and prognosis of EEC and adenocarcinoma was quantified using net reclassification improvement (NRI), propensity score matching (PSM), and Kaplan–Meier curves.
Results
Cox regression analysis identified age, race, marital status, tumor grade, tumor stage, tumor size, and chemotherapy as independent prognostic factors for OS. A nomogram for predicting OS was developed based on these factors. The C‐indexes for the OS nomogram was 0.743 and 0.720 for the SEER training set and external validation set, respectively. The area under the ROC (AUC) for the OS nomogram was 0.755, 0.757, and 0.741 for the SEER data subsets and 0.844, 0.719, and 0.743 for the external validation subsets. Calibration plots showed high concordance between the nomogram‐predicted and observed OS. DCA also demonstrated the clinical utility of the OS nomogram. NRI, PSM, and survival analyses revealed that tumor grade was the most important histopathological factor for EEC and adenocarcinoma prognosis.
Conclusion
Seven independent prognostic variables for the OS of patients with EEC and adenocarcinoma were identified. The established OS nomogram has good predictive ability and clinical utility and validates the 2023 endometrial cancer FIGO staging system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University), Hefei, Anhui, China.
- Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, Hefei, Anhui, China.
ORCID-Profile: Min Li
Förderung
- Anhui Provincial Department of Science and Technology
Zitieren
APA
Feng, Y., Miao, F., Li, Y., Li, M., & Cao, Y. (2024). Validating the 2023 FIGO staging system: A nomogram for endometrioid endometrial cancer and adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.7216
Vancouver
Feng Y, Miao F, Li Y, Li M, Cao Y. Validating the 2023 FIGO staging system: A nomogram for endometrioid endometrial cancer and adenocarcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.7216
BibTeX
@article{Feng2024,
author = {Feng, Yifan and Miao, Fulu and Li, Yuyang and Li, Min and Cao, Yunxia},
title = {Validating the 2023 FIGO staging system: A nomogram for endometrioid endometrial cancer and adenocarcinoma},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7216}
}
EUVIMED